1-(2-chloroethyl)-3-(3-methylisoxazol-5-yl)urea | 612480-86-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-(2-chloroethyl)-3-(3-methylisoxazol-5-yl)urea
• 英文别名: 1-(2-Chloroethyl)-3-(3-methyl-1,2-oxazol-5-yl)urea
• CAS: 612480-86-1
• 化学式: C₇H₁₀ClN₃O₂
• 分子量: 203.628
• InChiKey: LKVAZCXNEJIGKP-UHFFFAOYSA-N

物化性质

• 沸点：
  325.6±42.0 °C(Predicted)
• 密度：
  1.343±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  67.2
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(2-chloroethyl)-3-(3-methylisoxazol-5-yl)urea 在 sodium hydride 、 sodium carbonate 作用下， 以 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 18.0h， 生成 1-(2-bromo-benzyl)-3-(3-methyl-isoxazol-5-yl)-imidazolidin-2-one
  参考文献：
  名称：

  Synthesis and antileishmanial activity of new imidazolidin-2-one derivatives

  摘要：

  N-3-acyl, arylsulfonyl and benzyl derivatives of N-1-(4,6-dimethylpyridin-2-yl), (5-methylthiazol-2-yl) or (3-methylisoxazol-5-yl)imidazolidin-2-ones were synthesized and evaluated as potential antileishmanial agents. Determination of their cytotoxic effect was carried out using MRC5 cells. Two compounds, 1-(4,6-dimethylpyridin-2-yl)-3-(napht-2-ylsulfonyl)imidazolidin-2-one, 18, and 1-(3-methylisoxazol-5-yl)-3-(4-bromobenzyl)imidazo-lidin-2-one, 25, exerted significant antileishmanial activity in promastigotes of Leishmania (L) mexicana and Leishmania infantum, with IC50 in the range of 8-16 mumol L-1. Antiparasitical activity of the less toxic compound, 25, was confirmed against intracellular amastigote of L. mexicana, the clinical relevant stage; its low IC50 value (2.4 mumol L-1) and its favourable toxicity/activity index (11) constitute encouraging results for ongoing pharmacomodulation in the corresponding subseries. (C) 2003 Editions scientifiques et medicales Elsevier SAS. All rights reserved.

  DOI：

  10.1016/s0223-5234(03)00119-3
• 作为产物：
  描述：

  氯乙基异氰酸酯 、 3-甲基异恶唑-5-胺 以 氯仿 为溶剂， 反应 3.0h， 以89%的产率得到1-(2-chloroethyl)-3-(3-methylisoxazol-5-yl)urea
  参考文献：
  名称：

  Synthesis and antileishmanial activity of new imidazolidin-2-one derivatives

  摘要：

  N-3-acyl, arylsulfonyl and benzyl derivatives of N-1-(4,6-dimethylpyridin-2-yl), (5-methylthiazol-2-yl) or (3-methylisoxazol-5-yl)imidazolidin-2-ones were synthesized and evaluated as potential antileishmanial agents. Determination of their cytotoxic effect was carried out using MRC5 cells. Two compounds, 1-(4,6-dimethylpyridin-2-yl)-3-(napht-2-ylsulfonyl)imidazolidin-2-one, 18, and 1-(3-methylisoxazol-5-yl)-3-(4-bromobenzyl)imidazo-lidin-2-one, 25, exerted significant antileishmanial activity in promastigotes of Leishmania (L) mexicana and Leishmania infantum, with IC50 in the range of 8-16 mumol L-1. Antiparasitical activity of the less toxic compound, 25, was confirmed against intracellular amastigote of L. mexicana, the clinical relevant stage; its low IC50 value (2.4 mumol L-1) and its favourable toxicity/activity index (11) constitute encouraging results for ongoing pharmacomodulation in the corresponding subseries. (C) 2003 Editions scientifiques et medicales Elsevier SAS. All rights reserved.

  DOI：

  10.1016/s0223-5234(03)00119-3

文献信息

• Synthesis and antileishmanial activity of new imidazolidin-2-one derivatives
  作者：Jean-Michel H Robert、Caroline Sabourin、Nidia Alvarez、Sylvie Robert-Piessard、Guillaume Le Baut、Patrice Le Pape

  DOI：10.1016/s0223-5234(03)00119-3

  日期：2003.7

  N-3-acyl, arylsulfonyl and benzyl derivatives of N-1-(4,6-dimethylpyridin-2-yl), (5-methylthiazol-2-yl) or (3-methylisoxazol-5-yl)imidazolidin-2-ones were synthesized and evaluated as potential antileishmanial agents. Determination of their cytotoxic effect was carried out using MRC5 cells. Two compounds, 1-(4,6-dimethylpyridin-2-yl)-3-(napht-2-ylsulfonyl)imidazolidin-2-one, 18, and 1-(3-methylisoxazol-5-yl)-3-(4-bromobenzyl)imidazo-lidin-2-one, 25, exerted significant antileishmanial activity in promastigotes of Leishmania (L) mexicana and Leishmania infantum, with IC50 in the range of 8-16 mumol L-1. Antiparasitical activity of the less toxic compound, 25, was confirmed against intracellular amastigote of L. mexicana, the clinical relevant stage; its low IC50 value (2.4 mumol L-1) and its favourable toxicity/activity index (11) constitute encouraging results for ongoing pharmacomodulation in the corresponding subseries. (C) 2003 Editions scientifiques et medicales Elsevier SAS. All rights reserved.